Leerink Partnrs Has Negative Outlook of Immatics Q3 Earnings

Key Points

• Leerink Partners has downgraded its Q3 2025 earnings estimate for Immatics N.V. to a loss of ($0.50) per share, a decrease from the previous estimate of ($0.41).
• The consensus target price for Immatics currently stands at $14.67, with a rating of "Moderate Buy" from analysts; however, it includes mixed recommendations such as one sell, four buy, and one strong buy ratings.
• Immatics reported a loss of ($0.66) EPS in its latest quarterly earnings, missing the consensus estimate by ($0.28), with actual revenues of $6.48 million significantly below expectations of $13.05 million.

Immatics N.V. (NASDAQ:IMTX - Free Report) - Equities researchers at Leerink Partnrs dropped their Q3 2025 earnings estimates for shares of Immatics in a note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.50) for the quarter, down from their previous estimate of ($0.41). The consensus estimate for Immatics' current full-year earnings is ($0.72) per share. Leerink Partnrs also issued estimates for Immatics' Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.12) EPS and FY2026 earnings at ($1.81) EPS.

Immatics (NASDAQ:IMTX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.The business had revenue of $6.48 million for the quarter, compared to analysts' expectations of $13.05 million.

IMTX has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft started coverage on shares of Immatics in a research report on Wednesday, May 28th. They set a "buy" rating and a $10.00 price objective for the company. Finally, Zacks Research downgraded shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.67.

Immatics Stock Performance

Immatics stock traded up $0.06 during midday trading on Monday, hitting $5.69. 302,231 shares of the company's stock were exchanged, compared to its average volume of 583,837. Immatics has a 12-month low of $3.30 and a 12-month high of $13.09. The stock has a market cap of $691.62 million, a price-to-earnings ratio of -8.75 and a beta of 0.93. The firm's 50 day simple moving average is $6.00 and its 200 day simple moving average is $5.21.

Institutional Investors Weigh In On Immatics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. lifted its holdings in Immatics by 38.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock valued at $66,194,000 after acquiring an additional 4,072,226 shares during the period. Wellington Management Group LLP grew its holdings in Immatics by 7.6% in the fourth quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock valued at $74,071,000 after purchasing an additional 736,709 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in Immatics by 12.9% in the fourth quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company's stock valued at $51,731,000 after purchasing an additional 832,432 shares during the last quarter. Vestal Point Capital LP grew its holdings in Immatics by 14.6% in the first quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock valued at $32,439,000 after purchasing an additional 917,700 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP grew its holdings in Immatics by 38.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock valued at $38,496,000 after purchasing an additional 1,509,547 shares during the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.